Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly.

The purpose of this study was to determine the effect of serum lipids, lipoprotein fractions, and apolipoprotein (apo) A-1, B and E on mortality from vascular and nonvascular causes in an unselected elderly population. The random sample of 347 community-living individuals aged 65 years or older was obtained in 1982. Serum total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglyceride, and apo A-1, B and E were determined at baseline. After the 11-year follow-up, 199 of the participants had died, and 148 were still alive. Mortality data from vascular and nonvascular causes by the end of 1993 were obtained from official registers. In the univariate analysis, a low total cholesterol level was associated with death due to both vascular and nonvascular causes (P value for trend, .021 and .0027, respectively). After the adjustment for other risk factors, the inverse association between total cholesterol and vascular mortality disappeared, but low total cholesterol was still a significant predictor of death due to nonvascular causes. Adjusted relative risks (RRs) of death due to nonvascular causes for those with elevated total cholesterol (5.1 to 6.5, 6.6 to 8.0, and > 8.0 mmol/L) compared with the reference group (< or = 5.0 mmol/L) were 0.5 (95% confidence interval [CI], 0.2 to 1.2), 0.6 (0.2 to 1.0), and 0.2 (0 to 0.8), respectively. Neither concentrations of HDL-C, LDL-C, triglyceride, nor apo B were associated with vascular or nonvascular mortality. On the other hand, low concentration of apo A-1 predicted vascular death. The RR for the lowest tertile was 1.6 (1.1 to 2.5) compared with the highest tertile. Furthermore, the occurrence of the apo E e4 allele was associated with increased risk of vascular mortality (RR, 1.5; 95% CI, 1.0 to 2.2), but the risk was not related to the levels of lipids, lipoproteins, or other apolipoproteins at baseline. Nonvascular mortality also tended to be predicted by the presence of the e4 allele (RR, 1.5; 95% CI, 0.9 to 2.5). In an unselected elderly population, the allelic variation of apo E, i.e., the presence of the e4 allele, and a low concentration of apo A-1 were more accurate indicators of vascular mortality than total cholesterol or lipoprotein fractions. The risk associated with the apo E polymorphism is unrelated to dyslipidemia.

[1]  D. Kromhout,et al.  Total cholesterol concentration and mortality at a relatively young age: Do men and women differ? , 1995, BMJ.

[2]  R. Glynn,et al.  HDL cholesterol predicts coronary heart disease mortality in older persons. , 1995, JAMA.

[3]  P. Whincup,et al.  Low serum total cholesterol concentrations and mortality in middle aged British men , 1995, BMJ.

[4]  J. Stengård,et al.  Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. , 1995, Circulation.

[5]  H. Krumholz,et al.  Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. , 1994, JAMA.

[6]  M. Law,et al.  Assessing possible hazards of reducing serum cholesterol , 1994, BMJ.

[7]  A. Reunanen,et al.  Health-based reference values of the Mini-Finland Health Survey: 3. Triglycerides in total serum and in different lipoprotein fractions. , 1994, Scandinavian journal of clinical and laboratory investigation.

[8]  J. Stengård,et al.  Prevalence of coronary heart disease and associated risk factors among elderly Finnish men in the Seven Countries Study. , 1993, Atherosclerosis.

[9]  K C Cain,et al.  Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. , 1993, Archives of internal medicine.

[10]  C. Mamotte,et al.  Apolipoprotein ∈4 homozygosity in young men with coronary heart disease , 1992, The Lancet.

[11]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[12]  A. G. Shaper,et al.  Blood lipids: the relationship with alcohol intake, smoking, and body weight. , 1992, Journal of epidemiology and community health.

[13]  W. L. Ooi,et al.  Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx Aging Study. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[14]  M. Marmot,et al.  Plasma cholesterol concentration and mortality. The Whitehall Study. , 1992, JAMA.

[15]  M. Laakso,et al.  Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin dependent diabetes. , 1991, BMJ.

[16]  D. Salem,et al.  Prevalence of risk factors in men with premature coronary artery disease. , 1991, The American journal of cardiology.

[17]  C. Bulpitt,et al.  Is a high serum cholesterol level associated with longer survival in elderly hypertensives? , 1990, Journal of hypertension.

[18]  T. Lehtimäki,et al.  Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. , 1990, Journal of lipid research.

[19]  J. Huttunen,et al.  Apolipoprotein E4 homozygosity predisposes to serum cholesterol elevation during high fat diet. , 1990, Arteriosclerosis.

[20]  D R Jacobs,et al.  High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. , 1990, American journal of epidemiology.

[21]  M. Laakso,et al.  Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients. , 1989, American journal of epidemiology.

[22]  C. Isles,et al.  Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. , 1989, BMJ.

[23]  M. Nieminen,et al.  Apoprotein E Polymorphism and Coronary Artery Disease: Increased Prevalence of Apolipoprotein E‐4 in Angiographically Verified Coronary Patients , 1989, Arteriosclerosis.

[24]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[25]  W. Kannel,et al.  Proportional Hazards Analysis of Risk Factors for Coronary Heart Disease in Individuals Aged 65 or Older , 1988, Journal of the American Geriatrics Society.

[26]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[27]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.

[28]  Y. Xie,et al.  Studies on human apolipoprotein E genetic isoforms and their phenotypes among the Chinese population. , 1987, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College = Chung-kuo i hsueh k'o hsueh yuan, Chung-kuo hsieh ho i k'o ta hsueh hsueh pao.

[29]  R. Hoover,et al.  SERUM CHOLESTEROL AND CANCER IN THE NHANES I EPIDEMIOLOGIC FOLLOWUP STUDY , 1987, The Lancet.

[30]  C. Ehnholm,et al.  Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. , 1987, The Journal of clinical investigation.

[31]  D. Levy,et al.  Cholesterol and mortality. 30 years of follow-up from the Framingham study. , 1987, JAMA.

[32]  J. Cutler,et al.  Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. , 1987, JAMA.

[33]  J. Marniemi,et al.  Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. , 1987, Scandinavian journal of clinical and laboratory investigation.

[34]  K. Watanabe,et al.  Reciprocal effects of apolipoprotein E alleles (ε2 AND ε4) on plasma lipid levels in normolipidemic subjects , 1986 .

[35]  L. Curtiss,et al.  Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. , 1986, Journal of immunology.

[36]  G. Assmann,et al.  Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. , 1986, Clinical chemistry.

[37]  C. Ehnholm,et al.  Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. , 1986, Journal of lipid research.

[38]  E. Alanen,et al.  Levels of serum lipids, apolipoproteins A-I and B and pseudocholinesterase activity and their discriminative values in patients with coronary by-pass operation. , 1986, Atherosclerosis.

[39]  C. Sing,et al.  Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. , 1985, American journal of human genetics.

[40]  E. Barrett-Connor,et al.  Ischemic heart disease risk factors after age 50. , 1984, Journal of chronic diseases.

[41]  G. Assmann,et al.  Apolipoprotein E Polymorphism and Coronary Artery Disease , 1983, Arteriosclerosis.

[42]  M. Oliver.  SERUM CHOLESTEROL-THE KNAVE OF HEARTS AND THE JOKER , 1981, The Lancet.

[43]  G. Cazzolato,et al.  ARE APOLIPOPROTEINS BETTER DISCRIMINATORS THAN LIPIDS FOR ATHEROSCLEROSIS? , 1979, The Lancet.

[44]  C. Glueck,et al.  Lipid and lipoprotein distributions in octo- and nonagenarians. , 1979, Metabolism: clinical and experimental.

[45]  W. Kannel,et al.  Evaluation of cardiovascular risk in the elderly: the Framingham study. , 1978, Bulletin of the New York Academy of Medicine.

[46]  G. Kostner.  Letter: Enzymatic determination of cholesterol in high-density lipoprotein fractions prepared by polyanion precipitation. , 1976, Clinical chemistry.

[47]  G. Hyman,et al.  Letter: A shower of aortic aneurysms. , 1974, Lancet.

[48]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[49]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.